-+ 0.00%
-+ 0.00%
-+ 0.00%

Cullinan Therapeutics Licenses Rights To Velinotamig Fom Genrix Bio For Development In Autoimmune Diseases

Benzinga·06/04/2025 20:05:46
Listen to the news

Advances Cullinan's leadership in T cell engager (TCE) development for autoimmune diseases with both a CD19 TCE and BCMA TCE in its pipeline

Strengthens Cullinan portfolio of autoimmune programs with the opportunity to address a broader range of diseases while maintaining cash runway into 2028